Monitor for S-3 filing in coming weeks which could enable resale and increase share float; assess whether the clinical milestone met is material relative to trial endpoints. The extended cash runway reduces near-term financing risk, but no clinical data was released, evaluate upcoming trial readouts for value inflection.
LYEL drugs
LYEL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 9 $25.50entry
- T+1 · 8mo ago +0.51%α +0.69% · $25.63
- T+5 · 8mo ago −17.14%α −15.78% · $21.13
- T+20 · 7mo ago −14.59%α −11.78% · $21.78
- T+60 · 6mo ago −41.61%α −53.59% · $14.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lyell Immunopharma closed an additional $50 million tranche of its private placement, bringing total proceeds to $100 million, following a clinical milestone in its ronde-cel PiNACLE trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Officer to lead financial strategy amid this capital raise.
Key Financial Metrics
Key Facts
- Lyell closed an additional $50 million tranche of a $100 million private placement after achieving a clinical milestone in the ronde-cel PiNACLE trial.
- Total gross proceeds from the private placement are now $100 million, priced at $25.61 per share.
- Cash runway is expected to extend into Q2 2027.
- Smital Shah was appointed Chief Financial and Business Officer, effective March 9, 2026, bringing extensive biopharma finance and strategy experience.
- The securities were sold in a private placement without registration, with investors receiving Form S-3 resale registration rights.
Financial Impact
$50 million in new capital raised at $25.61/share, doubling prior tranche; total $100 million private placement now complete.
Risk Factors
- Dilution from $50 million in new shares issued, though pricing was at a fixed $25.61 (current stock price not disclosed).
- Forward-looking statements dominate; the clinical milestone is not described in detail, so its materiality is uncertain.
- Private placement may lead to increased share volatility once resale registration becomes effective.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251756 |
Track record
21 reports on LYEL
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers